Merck KGaA Joins Race To Develop Next-Gen PARP Inhibitors
Links Up With Italy’s Nerviano
PARP inhibitors have had great success in treating a number of cancers but the German major has placed a $65m bet that Nerviano's selective PARP1 approach could produce a safer and more efficacious option.
You may also be interested in...
Third Rock Ventures is leading a $102m series A for Synnovation, a cancer-focused biotech led by several former Incyte scientists. The new firm wants to develop best-in-class drugs against validated targets.
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
With the number of deals being inked in biopharma continuing apace, the UK firm spoke to Scrip about how to negotiate the line between what big pharma wants and what a biotech is likely to get.